Inactief instrument

Andere talen Sensidose AB

Aandelen

SENSI

SE0017232671

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Updated recommendation by the nomination committee of Navamedic ASA	31-05-23
Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	26-05-23
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer	26-05-23
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.	25-05-23
EQL Pharma AB publishes the final outcome in public takeover offer. As a result of the shareholder dynamics and other circumstances the Board also announces its intention to sell its holdings.	17-05-23
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.	17-05-23
Navamedic ASA Q1 2023: Another strong quarter	11-05-23
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag	10-05-23
Sensidose AB Reports Earnings Results for the First Quarter Ended March 31, 2023	05-05-23
Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	28-04-23
Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag	26-04-23
EQL Pharma extends the unconditional offer to include warrants series TO 1 and publishes a supplementary offer document regarding EQL Pharma's offer to the shareholders of Sensidose	26-04-23
Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1	25-04-23
Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag	24-04-23
Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag	24-04-23
Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published	24-04-23
Sweden’s EQL Pharma Increases Bid for Sensidose	24-04-23
EQL Pharma AB announces a revised unconditioned cash offer of SEK 8.40 per share to the shareholders of Sensidose Aktiebolag	24-04-23
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake	24-04-23
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB	22-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sensidose AB

Aandelen

SENSI

SE0017232671

Andere talen

Filters